## **Tidarat Nhukeaw**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6575121/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine. BMC Cancer, 2014, 14, 73.	2.6	31
2	Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPTA-EA1. Anti-Cancer Agents in Medicinal Chemistry, 2017, 17, 212-220.	1.7	27
3	Cellular responses of BRCA1-defective HCC1937 breast cancer cells induced by the antimetastasis ruthenium(II) arene compound RAPTA-T. Apoptosis: an International Journal on Programmed Cell Death, 2019, 24, 612-622.	4.9	12
4	Half-sandwich ruthenium (II) p-cymene complexes based on organophosphorus ligands: Structure determination, computational investigation, in vitro antiproliferative effect in breast cancer cells and antimicrobial activity. Polyhedron, 2021, 204, 115244.	2.2	7
5	DNA-binding properties of ruthenium(II) complexes with the bidentate ligand 5-chloro-2-(phenylazo)pyridine. Transition Metal Chemistry, 2012, 37, 207-214.	1.4	6
6	A photoactive iridium(III) complex with 3-methyl-2-phenyl pyridine and 1,1-bis(diphenylphosphino)methane: Synthesis, structural characterization and cytotoxicity in breast cancer cells. Journal of Coordination Chemistry, 2021, 74, 2380-2394.	2.2	4
7	Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib. Heliyon, 2021, 7, e07749.	3.2	3